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Introduction
Ultrasound (US) can be used to trigger the cytotoxicity of chemical compounds, known as sonosensitisers, to yield 
cancer cell death in an approach that has been defined sonodynamic therapy (SDT). Although SDT mechanisms are 
still a matter of debate between a cavitation-induced i) photo-activation via sonoluminescence or ii) homolytic splitting 
of water, it is generally accepted that reactive oxygen species (ROS) are the main effector of sonosensitised cell 
damage (1). Therefore, this work aims to investigate the US-responsiveness of different chemical compounds in an 
attempt to clarify the mechanisms underpinning the sonodynamic process
Methods
US were used to trigger the cytotoxicity of different chemical compounds at noncytotoxic concentrations per se, such 
as metalloporphyrin, i.e. Pd(II) porphyrin, and chemotherapeutic drugs, i.e. doxorubicin and paclitaxel. US-mediated 
ROS generation were analysed ex cellulo by EPR spectroscopy and in vitro by DCF-DA flow cytometric assay. The 
US-mediated anticancer activity of Pd(II) porphyrin, doxorubicin and paclitaxel was then evaluated on the human 
colon cancer, HT-29, the ovarian cancer, A2780, and the breast cancer, MCF-7, cell lines, respectively. Mitochondrial 
membrane potential, DNA damage, lipid peroxidation, cell cycle and cell death were analysed by flow cytometric 
assays and gene expression by real-time-RT-PCR
Results
Our results showed, through EPR analysis, that Pd(II) porphyrin and doxorubicin were more efficient in generating ROS 
under US exposure than paclitaxel with different patterns of ROS production under US exposure for each compound. 
These findings were also confirmed when noncytotoxic concentrations of Pd(II) porphyrin and doxorubicin, activated 
by US in HT-29 and A2780 cells, showed a significant intracellular ROS production and a remarkable reduction in 
cancer cell growth, along with significant mitochondrial membrane potential impairment and an increase in apoptotic 
and necrotic cells, respect to paclitaxel in MCF-7 cells. These results suggest that the US-responsiveness of the 
compounds can be related to their photosensitising properties
Discussion
Since Pd(II) porphyrin and doxorubicin, well known photosensitisers, were able to elicit a significant ROS generation 
yielding cancer cell death when triggered by US compared to paclitaxel, it might be reasonable to assume that the US-
mediated sonosensitiser activation can be due to a sort of photo-activation via cavitation-induced sonoluminescence 
rather than a radical path process via homolytic splitting of water
Conclusion
The results reported herein support the intracellular ROS generation as the main effector in the sonodynamic process 
and new insight in the underlying mechanism.
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